RenaGelRenagel (sevelamer hydrochloride)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved November 1998

Specific Treatments:


Therapeutic Areas

General Information

Nonabsorbed, oral, phosphate binding polymer hydrogel for the control of hyperphosphatemia in patients with end stage renal disease.

Mechanism of Action

The agent acts by binding phosphorus in the gastrointestinal tract and allows elimination of phosphorus through normal digestive processes.